Search

Displaying results 2951 - 2960 of 5419 in total
  1. Drug

    Debrisoquine

    go.drugbank.com/drugs/DB04840
    Approved

    An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize t...

  2. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.

  3. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    [L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma

  4. Drug

    Acetyl hexapeptide-3

    go.drugbank.com/drugs/DB11709
    Investigational

    Argireline has been used in trials studying the treatment of wrinkles.

    Mixtures: Ultra Protection Ultra Long-UVA
  5. Drug

    APD668

    go.drugbank.com/drugs/DB05166
    Experimental

    APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

  6. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).

  7. Drug

    AT-7519

    go.drugbank.com/drugs/DB08142
    Investigational

    It is developed by Astex for the treatment of solid tumours and haematological malignancies.

  8. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).

  9. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]

  10. Drug

    AS-8112

    go.drugbank.com/drugs/DB09207
    Experimental

    It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.